导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.68% | 2865/4773 |
| 近一周 | -2.49% | 3944/5465 |
| 近一月 | -6.93% | 4380/5421 |
| 近一季 | -14.10% | 4237/5231 |
| 近半年 | -3.60% | 2518/4920 |
| 近一年 | 0.47% | 2689/4394 |
| 近两年 | 56.90% | 1317/2954 |
| 近三年 | 27.74% | 1178/2253 |
| 成立以来 | 24.31% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.99% 2604/4961 |
20.02% 1258/5312 |
- - |
- - |
| 2025 | 25.79% 1682/4813 |
-0.45% 2256/3635 |
-0.66% 2993/4076 |
29.88% 1202/4524 |
-2.06% 3079/4813 |
| 2024 | 11.69% 1301/3463 |
0.41% 980/2808 |
-4.28% 1493/3014 |
18.66% 966/3129 |
-2.07% 1945/3463 |
| 2023 | -15.92% 1666/2656 |
4.31% 988/2280 |
-6.10% 1589/2385 |
-7.83% 1630/2515 |
-6.87% 1949/2655 |
| 2022 | -26.28% 1386/2207 |
-18.30% 1319/1919 |
8.15% 384/2016 |
-16.21% 1426/2113 |
-0.42% 1605/2208 |
| 2021 | -1.47% 802/1822 |
-4.67% 881/1255 |
9.90% 512/1330 |
-8.16% 1109/1466 |
2.40% 601/1822 |
| 2020 | - - |
- - |
- - |
9.77% 623/1164 |
16.63% 156/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 广发深证100ETF联接C VS. 长安沪深300非周期A(740101) |